OR WAIT null SECS
In this episode, hosts sit down for an in-depth discussion of the 11 person-centered algorithms for clinical decision-making featured in the AACE's 2023 Comprehensive Type 2 Diabetes Management Algorithm.
At the American Association of Clinical Endocrinology (AACE) 2023 annual meeting, the organization announced the publication of the 2023 Comprehensive Type 2 Diabetes Management Algorithm.
A set of 11 specific algorithms created to provide concise guidance for clinical decision-making in management of type 2 diabetes, the document, which was debuted on May 5, 2023, incorporates a person-centered approach to management, including considerations for lifestyle modification and treatment of overweight and obesity as well as treatment of cardiovascular risk factors.
"Over the last several years, the paradigm of diabetes treatment has changed from a strict focus on glucose control and a one-size-fits-all approach, to a personalized assessment that considers a person's existing risks for cardiac events or kidney failure, so we can choose the right medication to decrease those risks," said Susan L. Samson, MD, PhD, FRCPC, FACE, president-elect of AACE. "Therefore, the latest algorithm provides a road map to easily navigate care and treatment based on both glycemic control and other conditions to improve a person's health and quality of life."
The 11 specific algorithms included in the document were:
Of note, the algorithms for Profiles of Weight-Loss Medications and Vaccine Recommendations are new sections within the document. Outfitted with multiple infographics providing visual guidance to assist with decision-making, the consensus statement also offers a summary of details to support the visual guidance for each algorithm.
In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the Remote Monitoring Program at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down for an in-depth discussion surrounding the new algorithms and break down what and how they expect the new guidance to impact patient care.
Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care.